Literature DB >> 12048367

Time to AIDS from 1992 to 1999 in HIV-1-infected subjects with known date of infection.

Jean-Michel Tassie1, Sophie Grabar, Rémi Lancar, Jacqueline Deloumeaux, Michèle Bentata, Dominique Costagliola.   

Abstract

To estimate the change in AIDS incubation time during three periods characterized by different availability of antiretroviral treatments, data from the French Hospital Database on HIV of 4702 HIV-1-positive subjects with a documented date of infection were analyzed. Times from seroconversion to AIDS were compared in three periods: period 1 from January 1992 to June 1995 (monotherapy); period 2 from July 1995 to June 1996 (dual therapy); and period 3 from July 1996 to June 1999 (triple therapy). Nonparametric survival analyses were performed to account for staggered entries in the database and during each period. From periods 1 to 3, antiretroviral treatments were initiated earlier after infection, more subjects were treated, and the nature of regimens changed (25.6% of subjects were treated with monotherapy in period 1, 34.6% were treated with dual therapy in period 2, and 53.4% were treated with triple therapy in period 3). Compared with period 1, the relative hazard (RH) of AIDS was 0.31 in period 3 (95% confidence interval [CI]: 0.24-0.39). When comparing period 3 with period 2, the RH of AIDS was 0.36 (CI: 0.29-0.45). Assuming a log normal distribution, the median time to AIDS was estimated as 8.0 years in period 1 (CI: 6.0-10.6), 9.8 years in period 2 (CI: 8.5, 11.2), and 20.0 years in period 3 (CI: 17.1-23.3). This lengthening in time to AIDS from 1992 to 1999 was particularly marked in the period after the introduction of triple therapy, including protease inhibitors.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12048367     DOI: 10.1097/00042560-200205010-00011

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  8 in total

1.  Back-calculation and projection of the HIV/AIDS epidemic among homosexual/ bisexual men in three European countries: evalution of past projections and updates allowing for treatment effects.

Authors:  Marc Artzrouni
Journal:  Eur J Epidemiol       Date:  2004       Impact factor: 8.082

2.  Including pre-AIDS mortality in back-calculation model to estimate HIV prevalence in France, 2000.

Authors:  Sylvie Deuffic-Burban; Dominique Costagliola
Journal:  Eur J Epidemiol       Date:  2006-05-23       Impact factor: 8.082

3.  HIV status of sexual partners is more important than antiretroviral treatment related perceptions for risk taking by HIV positive MSM in Montreal, Canada.

Authors:  J Cox; J Beauchemin; R Allard
Journal:  Sex Transm Infect       Date:  2004-12       Impact factor: 3.519

4.  A comparison of ad hoc methods to account for non-cancer AIDS and deaths as competing risks when estimating the effect of HAART on incident cancer AIDS among HIV-infected men.

Authors:  Meredith S Shiels; Stephen R Cole; Joan S Chmiel; Joseph Margolick; Jeremy Martinson; Zuo-Feng Zhang; Lisa P Jacobson
Journal:  J Clin Epidemiol       Date:  2009-10-31       Impact factor: 6.437

5.  Etravirine: a second-generation NNRTI for treatment-experienced adults with resistant HIV-1 infection.

Authors:  Joshua J Minuto; Richard Haubrich
Journal:  Futur HIV Ther       Date:  2008-11-01

6.  Effect of HAART on incident cancer and noncancer AIDS events among male HIV seroconverters.

Authors:  Meredith S Shiels; Stephen R Cole; Scott Wegner; Haroutune Armenian; Joan S Chmiel; Anuradha Ganesan; Vincent C Marconi; Otoniel Martinez-Maza; Jeremy Martinson; Amy Weintrob; Lisa P Jacobson; Nancy F Crum-Cianflone
Journal:  J Acquir Immune Defic Syndr       Date:  2008-08-01       Impact factor: 3.731

7.  Effect of highly active antiretroviral therapy on incident AIDS using calendar period as an instrumental variable.

Authors:  Lauren E Cain; Stephen R Cole; Sander Greenland; Todd T Brown; Joan S Chmiel; Lawrence Kingsley; Roger Detels
Journal:  Am J Epidemiol       Date:  2009-03-24       Impact factor: 4.897

8.  The relationship of reported HIV risk and history of HIV testing among emergency department patients.

Authors:  Roland C Merchant; Sarah M Freelove; Thomas J Langan; Melissa A Clark; Kenneth H Mayer; George R Seage; Victor G DeGruttola
Journal:  Postgrad Med       Date:  2010-01       Impact factor: 3.840

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.